Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Mydecine Innovations Group ($MYCO | $MYCOF) announced that the FDA has cleared MYCO-001 in a recent IND application, marking the first clearance of Mydecine's drug product. The Investigator Initiated trial is funded by a $4 million grant from the National Institutes of Health, making this the first time in 50 years the U.S. government has funded a study evaluating a psychedelic compound for therapeutic use. Press Release
Nova Mentis Life Science ($NOVA | $NMLSF) filed a patent on diagnosing, monitoring and treating neurological diseases with psilocybin and psilocybin-based tryptamine derivatives. Nova Mentis recently successfully completed a preclinical study that confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS. Press Release
Revitalist Lifestyle And Wellness ($CALM | $RVLWF) closed their second tranche of its private placement, bringing the total gross proceeds raised to $3.9 million. Since opening their first clinic in 2018, Revitalist has provided thousands of ketamine infusions. Press Release
Braxia Scientific ($BRAX | $BRAXF) opened their newest Braxia Health clinic in Ontario, focused on intravenous and oral ketamine, and psilocybin for treatment resistant depression and other mental health disorders. This is Braxia's fifth Health Clinic in Canada. Press Release
Awakn Life Sciences ($AWKN | $AWKNF) provided operational updates. Highlights included the completetion of the world's first Ketamine study for a range of behavioral addictions, regulatory approval for flagship clinic in London to begin delivering treatments and initiated a follow-on behavioral study investigating ketamine as a treatment for gambling disorder. Press Release
Irwin Naturals ($IWIN | $IWINF) acquired Preventive Medicine, a clinic operation based in Colchester, Vermont. This is Irwin Naturals' eighth ketamine clinic, which now covers four states. Press Release
Beckley Psytech (Private) partnered with Ksana Health to support the collection and analysis of digital behavioural data in Beckley Psytech’s upcoming Phase II studies evaluating the use of DMT in combination with psychotherapy as a potential treatment of treatment resistant depression. Press Release
Filament Health ($FH | $FLHLF) announced that a patient has been dosed with one of Filament's drug candidates through the Health Canada Special Access Program. Press Release
Psychedelic Finance: Interview With Amanda Feilding Of Beckley Foundation
Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.